agilon health Second Quarter 2025 Earnings: Misses Expectations

August 06, 2025

Simply Wall St

NYSE:AGL 1 Year Share Price vs Fair Value

Explore agilon health's Fair Values from the Community and select yours

agilon health (NYSE:AGL) Second Quarter 2025 Results

Key Financial Results

Revenue: US$1.39b (down 5.9% from 2Q 2024).
Net loss: US$104.4m (loss widened by 240% from 2Q 2024).
US$0.25 loss per share (further deteriorated from US$0.075 loss in 2Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

earnings-and-revenue-growth — NYSE:AGL Earnings and Revenue Growth August 6th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

agilon health Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 5.2%. Earnings per share (EPS) also missed analyst estimates by 114%.

Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are down 54% from a week ago.

Risk Analysis

You still need to take note of risks, for example - agilon health has 2 warning signs (and 1 which doesn't sit too well with us) we think you should know about.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.